Meridian Dairy Days is just a few days away, and one of the most important events is the dairy goat and cattle shows that ...

When Lilly Meister entered the portal in late March after three seasons with the Indiana women’s basketball team, she was ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

Shares of Verve Therapeutics ( VERV 76.56%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly ( LLY -0.90%) and Verve Therapeutics announced a "definitive ...

Hi, it’s Dong Cao and Manuel Baigorri in Hong Kong, looking at how some big-name international brands are reassessing their approach to business in China. Also today, Eli Lilly’s latest move to build ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

NEW YORK (AP) — U.S. stocks are nudging lower on Tuesday, and oil prices are rising again. It’s a modest return to form for ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...